HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02696 HENLIUS

Trading 03-18 15:26:04

67.200

+1.050

+1.59%

High67.900	Low66.000	Vol209.37K
Open67.250	D1 Closing66.150	Amplitude2.87%
Mkt Cap36.49B	Tradable Cap23.26B	Total Shares543.00M
T/O14.03M	T/O Rate0.06%	Tradable Shares346.07M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"HENLIUS","latestPrice":67.2,"timestamp":1773818724825,"preClose":66.15,"halted":0,"volume":209367,"delay":0,"changeRate":0.015873015873015827,"floatShares":346074397,"shares":543000000,"eps":1.720845481936682,"marketStatus":"Trading","change":1.05,"latestTime":"03-18 15:26:04","open":67.25,"high":67.9,"low":66,"amount":14031488,"amplitude":0.028723,"askPrice":67.3,"askSize":1600,"bidPrice":67.2,"bidSize":4100,"shortable":3,"etf":0,"ttmEps":1.7288705268108389,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1773821400000},"marketStatusCode":2,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":66.15,"openAndCloseTimeList":[[1773797400000,1773806400000],[1773810000000,1773820800000]],"volumeRatio":0.502228,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696/wiki","defaultTab":"wiki","newsList":[{"id":"1100647427","title":"HENLIUS CEO Zhu Jun on the 'First Principle' in Pharma: Daring to Tackle Challenges Others Avoid","url":"https://stock-news.laohu8.com/highlight/detail?id=1100647427","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100647427?lang=en_us&edition=fundamental","pubTime":"2026-03-18 15:05","pubTimestamp":1773817553,"startTime":"0","endTime":"0","summary":"At the 2026 Yabuli Forum Annual Meeting held from March 17 to 19 in Heilongjiang, HENLIUS CEO Zhu Jun delivered a speech. Zhu Jun noted that the company was selected last year as one of Forbes' 50...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","HK0000320264.USD","HK0000306701.USD","HK0000320223.HKD","HK0000165453.HKD","BK1161","HK0000306685.HKD"],"gpt_icon":0},{"id":"1192730058","title":"Hong Kong Market Announcements: Ant Group's Acquisition of Bright Smart Receives Approval, Trading Resumes March 17","url":"https://stock-news.laohu8.com/highlight/detail?id=1192730058","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192730058?lang=en_us&edition=fundamental","pubTime":"2026-03-17 09:18","pubTimestamp":1773710304,"startTime":"0","endTime":"0","summary":"Major Corporate Developments: Hengrui Pharma (01276) announced that its SHR-1819 injection and SHR-1905 injection have received drug clinical trial approval notices. Henlius (02696) disclosed that...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"86c6cd7c917d7913316e328a31a00c76","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01428","BK4588","02565","LU0359201612.USD","HK0000320223.HKD","LU0359202008.SGD","BK1606","02696","VXUS","LU2543165471.USD","01276","BK1521","HK0000320264.USD","06688","HK0000165453.HKD","BK1197","HK0000306701.USD","BK1147","LU1023057109.AUD","LU0359201885.HKD","BK4585","00874","HK0000306685.HKD","BK1161","BK1191","BK1515"],"gpt_icon":1},{"id":"2619451243","title":"BRIEF-Shanghai Henlius Biotech Inc Says NMPA Approves IND Application For Hlx07 And Hansizhuang Combination In SQNSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2619451243","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619451243?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:27","pubTimestamp":1773656857,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Henlius Biotech Inc Says NMPA Approves IND Application For Hlx07 And Hansizhuang Combination In SQNSCLCMarch 16  - Shanghai Henlius Biotech Inc 2696.HK:NMPA APPROVES IND APPLICATION FOR HLX07 AND HANSIZHUANG COMBINATION IN SQNSCLCFurther company coverage: 2696.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN40302G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320264.USD","HK0000306685.HKD","HK0000320223.HKD","HK0000165453.HKD","HK0000306701.USD","02696","BK1161"],"gpt_icon":0},{"id":"1125082253","title":"HENLIUS Obtains NMPA Clearance for Clinical Trial of Pimurutamab HLX07 Combination Therapy in Advanced Squamous Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1125082253","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125082253?lang=en_us&edition=fundamental","pubTime":"2026-03-16 17:48","pubTimestamp":1773654501,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) announced that the clinical trial application for its self-developed pimurutamab HLX07 (recombinant anti-EGFR humanized monoclonal antibody injection) in combination with HANSIZHUANG®...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","HK0000306685.HKD","HK0000306701.USD","BK1161","HK0000320264.USD","HK0000165453.HKD","HK0000320223.HKD"],"gpt_icon":0},{"id":"2619459345","title":"Shanghai Henlius Biotech Inc - Nmpa Approves Ind Application for Hlx07 and Hansizhuang Combination in Sqnsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2619459345","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619459345?lang=en_us&edition=fundamental","pubTime":"2026-03-16 17:45","pubTimestamp":1773654308,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN40302G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000320223.HKD","HK0000306701.USD","02696","HK0000306685.HKD","BK1161","HK0000320264.USD","HK0000165453.HKD"],"gpt_icon":0},{"id":"2619843459","title":"NMPA approves Henlius IND trial of HLX07 combo for advanced squamous NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2619843459","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619843459?lang=en_us&edition=fundamental","pubTime":"2026-03-16 17:44","pubTimestamp":1773654291,"startTime":"0","endTime":"0","summary":"Henlius said China’s National Medical Products Administration approved an investigational new drug application to start a clinical trial of pimurutamab HLX07 with serplulimab  and chemotherapy for advanced squamous non-small cell lung cancer. The company said no similar combination has been approved for marketing globally as of the announcement date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 16, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL45QgNv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306685.HKD","BK1230","BK1161","00656","HK0000320223.HKD","HK0000320264.USD","02696","HK0000306701.USD","HK0000165453.HKD"],"gpt_icon":0},{"id":"2618600442","title":"BUZZ-Shanghai Henlius Biotech rises most in 5 months on new drug application","url":"https://stock-news.laohu8.com/highlight/detail?id=2618600442","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618600442?lang=en_us&edition=fundamental","pubTime":"2026-03-10 11:55","pubTimestamp":1773114940,"startTime":"0","endTime":"0","summary":"BUZZ-Shanghai Henlius Biotech rises most in 5 months on new drug application ** Shares of Shanghai Henlius Biotech Inc 2696.HK rise 8% to HK$71.25, on track for the biggest one-day pct gain since Octo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nL1N3ZY046:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306685.HKD","HK0000320264.USD","02696","HK0000320223.HKD","BK1161","BK1230","HK0000165453.HKD","00656","HK0000306701.USD"],"gpt_icon":0},{"id":"1158284845","title":"HENLIUS Shares Surge Over 8% Following Clinical Trial Approval for Innovative Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1158284845","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158284845?lang=en_us&edition=fundamental","pubTime":"2026-03-10 11:14","pubTimestamp":1773112466,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) saw its shares rise more than 8%, extending recent gains. At the time of writing, the stock was up 5.08%, trading at HK$69.3, with a turnover of HK$33.731 million. The upward movement...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4588","HK0000306701.USD","HK0000320223.HKD","VXUS","02696","BK4585","HK0000165453.HKD","HK0000320264.USD","HK0000306685.HKD"],"gpt_icon":0},{"id":"2618622094","title":"Assessing Shanghai Henlius Biotech’s Valuation As HLX11 And HLX22 Breast Cancer Programs Gain Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2618622094","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618622094?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:20","pubTimestamp":1773058837,"startTime":"0","endTime":"0","summary":"Why HLX11 and HLX22 are in focus for Shanghai Henlius Biotech (SEHK:2696)\nShanghai Henlius Biotech (SEHK:2696) is back on investors’ radar after two breast cancer program updates, including a positive CHMP opinion in Europe for its Perjeta biosimilar HLX11 and progress in its HER2 combination study HLX22 plus HLX87 in China.\nSee our latest analysis for Shanghai Henlius Biotech.\nEven after a 4.42% one day share price decline to HK$65.95, Shanghai Henlius Biotech’s 12.54% year to date share...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/assessing-shanghai-henlius-biotechs-valuation-as-hlx11-and-h","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/assessing-shanghai-henlius-biotechs-valuation-as-hlx11-and-h","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","HK0000320223.HKD","HK0000165453.HKD","HK0000306685.HKD","HK0000306701.USD","DCF","HK0000320264.USD","02696"],"gpt_icon":0},{"id":"2618647377","title":"BRIEF-Shanghai Henlius Biotech Says NMPA Approves IND Application For Phase 1 Trial HLX316","url":"https://stock-news.laohu8.com/highlight/detail?id=2618647377","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618647377?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:28","pubTimestamp":1773052080,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Henlius Biotech Says NMPA Approves IND Application For Phase 1 Trial HLX316March 9 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK:NMPA APPROVES IND APPLICATION FOR PHASE 1 TRIAL OF HLX316Further company coverage: 2696.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nFWN3ZU1GL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320264.USD","HK0000306685.HKD","HK0000320223.HKD","HK0000165453.HKD","HK0000306701.USD","02696","BK1161"],"gpt_icon":0},{"id":"1139124998","title":"Henlius (02696) Secures NMPA IND Approval for First-in-Class Tetra-Specific Antibody HLX3901 Targeting Advanced Solid Tumours","url":"https://stock-news.laohu8.com/highlight/detail?id=1139124998","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139124998?lang=en_us&edition=fundamental","pubTime":"2026-03-09 16:43","pubTimestamp":1773045835,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech, Inc. (HENLIUS, 02696) has obtained National Medical Products Administration (NMPA) clearance to initiate a Phase 1 clinical trial of HLX3901, its in-house developed...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"gpt_icon":0},{"id":"1147630357","title":"Henlius (02696): NMPA Approves IND for First-in-Class B7-H3-Targeting Sialidase Fusion Protein HLX316 in Advanced Solid Tumours","url":"https://stock-news.laohu8.com/highlight/detail?id=1147630357","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147630357?lang=en_us&edition=fundamental","pubTime":"2026-03-09 16:43","pubTimestamp":1773045806,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech, Inc. (Stock Code: 02696; “Henlius”) has obtained National Medical Products Administration clearance for a Phase I investigational new drug (IND) study of HLX316, a...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"gpt_icon":0},{"id":"1191528292","title":"HENLIUS Gains NMPA Clearance for Phase 1 Trial of HLX3901 in Advanced/Metastatic Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=1191528292","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191528292?lang=en_us&edition=fundamental","pubTime":"2026-03-09 16:34","pubTimestamp":1773045269,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) has announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for a Phase 1 clinical trial of HLX3901 injection, a DLL3xDLL3xCD3xCD28 tetra-specific antibody, in patients with advanced or metastatic solid tumors.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306685.HKD","HK0000165453.HKD","HK0000306701.USD","02696","HK0000320264.USD","HK0000320223.HKD","BK1161"],"gpt_icon":0},{"id":"2618469436","title":"China NMPA approves Shanghai Henlius IND for HLX3901 phase 1 trial in advanced solid tumours","url":"https://stock-news.laohu8.com/highlight/detail?id=2618469436","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618469436?lang=en_us&edition=fundamental","pubTime":"2026-03-09 16:31","pubTimestamp":1773045090,"startTime":"0","endTime":"0","summary":"Shanghai Henlius said China’s National Medical Products Administration approved its investigational new drug application for a Phase 1 clinical trial of HLX3901 injection in advanced or metastatic solid tumours. HLX3901 is a DLL3xDLL3xCD3xCD28 tetra-specific antibody. Henlius said no comparable tetra-specific antibody targeting DLL3 dual epitopes, CD3 and CD28 has been approved globally.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL5Kqlr3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","HK0000306701.USD","HK0000320264.USD","BK1161","00656","BK1230","HK0000320223.HKD","HK0000306685.HKD","02696"],"gpt_icon":0},{"id":"2618980646","title":"Shanghai Henlius Biotech - Nmpa Approves Ind Application for Phase 1 Trial of Hlx3901 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2618980646","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618980646?lang=en_us&edition=fundamental","pubTime":"2026-03-09 16:31","pubTimestamp":1773045062,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nFWN3ZU1LH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000165453.HKD","HK0000320223.HKD","02696","HK0000320264.USD","HK0000306685.HKD","HK0000306701.USD","BK1161"],"gpt_icon":0},{"id":"1119625768","title":"HENLIUS Shares Surge Over 5% on IND Approval for Proprietary HLX97 Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=1119625768","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119625768?lang=en_us&edition=fundamental","pubTime":"2026-03-06 10:14","pubTimestamp":1772763258,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) saw its shares rise more than 5%. At the time of writing, the stock was up 5.02%, trading at HK$68, with a turnover of HK$19.48 million. The increase follows an announcement on March...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","HK0000306701.USD","IND","VXUS","HK0000320223.HKD","HK0000306685.HKD","VT","HK0000320264.USD","BK1161","BK4588","BK4585","HK0000165453.HKD"],"gpt_icon":0},{"id":"1143997039","title":"HENLIUS (Stock Code: 02696) Announces IND Approval for KAT6A/B Inhibitor HLX97 in Advanced/Metastatic Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=1143997039","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143997039?lang=en_us&edition=fundamental","pubTime":"2026-03-05 17:33","pubTimestamp":1772703182,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech, Inc. announced that its investigational new drug application for HLX97 (a KAT6A/B small molecule inhibitor) has been approved by the National Medical Products Administration...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"gpt_icon":0},{"id":"2617517626","title":"Shanghai Henlius Biotech - Investigational New Drug Application for Clinical Trial of Hlx97 (Kat6a/B Small Molecule Inhibitor) Approved by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2617517626","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617517626?lang=en_us&edition=fundamental","pubTime":"2026-03-05 17:20","pubTimestamp":1772702450,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nFWN3ZS2AJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02696","HK0000306701.USD","HK0000320223.HKD","HK0000306685.HKD","HK0000320264.USD","BK1161","HK0000165453.HKD"],"gpt_icon":0},{"id":"2617517267","title":"China NMPA approves Henlius HLX97 IND for Phase 1 solid tumor trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2617517267","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617517267?lang=en_us&edition=fundamental","pubTime":"2026-03-05 17:20","pubTimestamp":1772702439,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. said China’s National Medical Products Administration has approved its investigational new drug application to begin a Phase 1 clinical trial of HLX97, a KAT6A/B small-molecule inhibitor, in patients with advanced or metastatic solid tumors. The company noted that no KAT6A/B small-molecule inhibitor has been approved for marketing globally as of the announcement date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL4Hjl3h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306701.USD","HK0000165453.HKD","HK0000320264.USD","BK1161","00656","BK1230","02696","HK0000320223.HKD","HK0000306685.HKD"],"gpt_icon":0},{"id":"1111521302","title":"Henlius (02696) Reports Conversion of 182.65 Million Unlisted Shares into H Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1111521302","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111521302?lang=en_us&edition=fundamental","pubTime":"2026-03-04 18:21","pubTimestamp":1772619671,"startTime":"0","endTime":"0","summary":"Henlius (02696) published its February 2026 Monthly Return, highlighting a significant increase in issued H shares and a corresponding decrease in unlisted shares. As of February 28, 2026, authorized...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0475},{"period":"1month","weight":-0.0597},{"period":"3month","weight":0.0907},{"period":"6month","weight":-0.1957},{"period":"1year","weight":1.1904},{"period":"ytd","weight":0.1595}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":-0.0263},{"period":"3month","weight":0.0157},{"period":"6month","weight":-0.0255},{"period":"1year","weight":0.0714},{"period":"ytd","weight":0.0093}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Shanghai Henlius Biotech Inc is a China-based company principally engaged in biopharmaceutical research and development, biopharmaceutical services and biopharmaceutical production and sales. The Company’s main products include HANQUYOU (trastuzumab for injection), HANNAIJIA (neratinib maleate), HANSIZHUANG (serplulimab injection), HANLIKANG (rituximab injection), HANDAYUAN (adalimumab injection), HANBEITAI (bevacizumab injection) and others. The Company’s products are mainly used in the treatment of adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, metastatic non-squamous non-small cell lung cancer, polyarticular juvenile idiopathic arthritis and others. The Company mainly operates its businesses in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044394},{"month":2,"riseRate":0.714286,"avgChangeRate":0.117695},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.016485},{"month":4,"riseRate":0.833333,"avgChangeRate":0.128587},{"month":5,"riseRate":0.5,"avgChangeRate":-0.024483},{"month":6,"riseRate":0.666667,"avgChangeRate":0.109389},{"month":7,"riseRate":0.5,"avgChangeRate":0.069459},{"month":8,"riseRate":0.5,"avgChangeRate":-0.024213},{"month":9,"riseRate":0,"avgChangeRate":-0.127435},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.025526},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058675},{"month":12,"riseRate":0.714286,"avgChangeRate":-0.023816}],"exchange":"SEHK","name":"HENLIUS","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest HENLIUS(02696) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"HENLIUS,02696,HENLIUS股票,HENLIUS股票老虎,HENLIUS股票老虎国际,HENLIUS行情,HENLIUS股票行情,HENLIUS股价,HENLIUS股市,HENLIUS股票价格,HENLIUS股票交易,HENLIUS股票购买,HENLIUS股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest HENLIUS(02696) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}